A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Latest Information Update: 10 Jul 2023
At a glance
- Drugs TAS 1553 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Astex Pharmaceuticals
- 06 Jul 2023 Status changed from active, no longer recruiting to discontinued.
- 16 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 11 Jan 2021 Status changed from not yet recruiting to recruiting.